Ocular non-Hodgkin’s lymphoma: a clinical study of nine cases
BACKGROUND Primary oculocerebral large cell malignant non-Hodgkin’s lymphoma, formerly called ocular reticulum cell sarcoma, runs a uniformly fatal course. Once the central nervous system (CNS) is involved, survival without treatment is very limited. Although treatment does not substantially improve...
Saved in:
Published in | British journal of ophthalmology Vol. 81; no. 1; pp. 31 - 36 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
BMA House, Tavistock Square, London, WC1H 9JR
BMJ Publishing Group Ltd
01.01.1997
BMJ BMJ Publishing Group LTD |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | BACKGROUND Primary oculocerebral large cell malignant non-Hodgkin’s lymphoma, formerly called ocular reticulum cell sarcoma, runs a uniformly fatal course. Once the central nervous system (CNS) is involved, survival without treatment is very limited. Although treatment does not substantially improve the long term survival, it provides short term improvement in these patients. METHODS The charts of all patients with ocular involvement of non-Hodgkin’s lymphoma followed during the period 1984–93 were reviewed. The diagnosis of non-Hodgkin’s lymphoma was made by different diagnostic approaches: CNS biopsy, anterior chamber tap, vitrectomy, haematology, and necropsy. RESULTS Eight patients had oculocerebral large cell and one had small cell non-Hodgkin’s lymphoma. Five patients with pure ocular localisation had initially received steroid treatment for intermediate uveitis. First diagnosis was made on CNS biopsy in three, anterior chamber tap in one, vitreous aspirate in three, haematology in one, and necropsy in one case. CONCLUSION Ocular non-Hodgkin’s lymphoma is a difficult diagnosis. Vitrectomy allows cytological diagnosis in most but not all cases. When no treatment is given, patients survive for only a few weeks once the CNS is involved. Although the disease is eventually fatal, treatment by means of radiotherapy, steroid administration, and vitrectomy can allow these patients to lead a normal professional and social life during the years between recurrences. |
---|---|
Bibliography: | Hugo Verbraeken, Department of Ophthalmology, University Hospital of Ghent, De Pintelaan, 185, 9000 Ghent, Belgium. istex:3D901E337411FF6C24A78918979E0F7457993BA0 href:bjophthalmol-81-31.pdf ark:/67375/NVC-P2G755W7-C local:bjophthalmol;81/1/31 PMID:9135405 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0007-1161 1468-2079 |
DOI: | 10.1136/bjo.81.1.31 |